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We have generated a codon-optimized hGagp17p24–Polp51 plasmid DNA expressing the human immunodeficiency virus type 1 (HIV-1)
Gag–Pol fusion protein that consists of clusters of highly conserved cytotoxic T lymphocyte (CTL) epitopes presented by multiple MHC
class I alleles. In the hGagp17p24–Polp51 construct, the ribosomal frameshift site had been deleted together with the potentially
immunosuppressive Gag nucleocapsid (p15) as well as Pol protease (p10) and integrase (p31). Analyses of the magnitude and breadth of
cellular responses demonstrated that immunization of HLA-A2/Kb transgenic mice with the hGagp17p24–Polp51 construct induced 2- to 5-
fold higher CD8+ T-cell responses to Gag p17-, p24-, and Pol reverse transcriptase (RT)-specific CTL epitopes than the full-length hGag–
PolDFsDPr counterpart. The increases were correlated with higher protection against challenge with recombinant vaccinia viruses (rVVs)
expressing gag and pol gene products. Consistent with the profile of Gag- and Pol-specific CD8+ T cell responses, an elevated level of type 1
cytokine production was noted in p24- and RT-stimulated splenocyte cultures established from hGagp17p24–Polp51-immunized mice
compared to responses induced with the hGag–PolDFsDPr vaccine. Sera of mice immunized with the hGagp17p24–Polp51 vaccine also
exhibited an increased titer of p24- and RT-specific IgG2 antibody responses. The results from our studies provide insights into approaches
for boosting the breadth of Gag- and Pol-specific immune responses.
D 2004 Elsevier Inc. All rights reserved.
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Strong cytotoxic T lymphocyte (CTL) responses are likely
to be an important aspect of an effective HIV-1 vaccine, as
their benefit has been established in simian immunodefi-
ciency virus (SIV) vaccination studies and in natural infec-
tions (Barouch and Letvin, 2000; Betts et al., 1999; Goulder
et al., 1997; Kaul et al., 2001b; McMichael and Rowland-
Jones, 2001). HIV-1-specific CD8+ Tcell responses have also0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.09.043
* Corresponding author. Fax: +1 716 845 8906.
E-mail address: danuta.kozbor@roswellpark.org (D. Kozbor).been detected in HIV-1 persistently exposed seronegative
individuals, suggesting a protective effect (Bernard et al.,
1999; Kaul et al., 2001a). Depletion of CD8+ T cells during
primary SIV infection of macaques resulted in uncontrolled
viremia (Borrow et al., 1994; Jin et al., 1999; Schmitz et al.,
1999). Similarly, studies in HIV-1-infected patients revealed
that partial control of viremia during acute infection
correlated with the appearance of HIV-1-specific CD8+ T
cells (Borrow et al., 1994; Koup et al., 1994), and escape from
CTL recognition has been linked to disease progression
(Evans et al., 1999a; Goulder et al., 1997). Thus, the evasion
of the host CTL response through mutation of key epitopes05) 467–479
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immune control of HIV-1 (Gaschen et al., 2002; Korber et al.,
2001; Walker and Korber, 2001).
Vaccine strategies that have been developed to address
HIV-1 variation include the use of subtype-based ancestral or
consensus sequences (Ellenberger et al., 2002; Korber et al.,
2001; Novitsky et al., 2002) and the use of highly conserved
regions or epitopes (Wilson et al., 2003). The logic behind
the latter approach is that these regions of the HIV-1 genome
are conserved because mutations would negatively impact
gene function of the virus. For these reasons, significant
efforts have been made to identify conserved HLA-restricted
CTL epitopes important for the control of HIV-1 infection.
More than 300 peptides containing CTL epitopes have been
reported to the HIV-1 Molecular Database, of which
approximately 150 have been optimally defined (Goulder
et al., 2001). The distribution of epitopes targeted within
these proteins is highly variable, with clustering within
relatively conserved regions of the virus (Walker and Korber,
2001; Yusim et al., 2002). Interestingly, the majority of the
clustered CTL epitopes also contains multiple class II-
restricted T helper (Th) determinants (Korber et al., 2003).
The presence of relatively conserved and highly immu-
nogenic CTL epitope clusters in the HIV-1 Gag–Pol region
suggests that the immunization strategy that would lead to
enhanced cellular responses to these regions would likely be
more effective than immunization with the entire protein. In
addition, the full-length Gag–Pol antigen contains regula-
tory regions that may negatively control protein expression
and affect the overall level of immune responses (Fu et al.,
1998). For example, expression of HIV-1 Gag–Pol yields
the Gag and the Gag–Pol precursor proteins in infected cells
in a 20:1 ratio due to translation of the latter protein through
ribosomal frameshifting mechanism (Wilson et al., 1988).
The disproportional production of Gag vs. Pol was
suggested to be responsible for the low immunogenicity
of Pol in numerous nonhuman primates and human studies
using DNAvaccines or recombinant viral vectors containing
Gag–Pol genes (Evans et al., 1999b; Huang et al., 2001;
Seth et al., 2000). Recently, results of three independent
studies have demonstrated that deletion of the frameshift site
in messenger RNA corresponding to the Gag–Pol fusion
protein resulted in the expression of Gag and Pol in a 1:1
ratio and enhanced Pol-specific immune response in
comparison to the response observed with the native
Gag–Pol gene (Huang et al., 2001; Kmieciak et al., 2001;
zur Megede et al., 2003). However, the effect of deletions or
modifications of distinct domains within the Gag–Pol fusion
protein with possible inhibitory activity on the induction of
immune responses has not been extensively explored.
In an effort to maximize the breadth and safety of the
Gag–Pol vaccine, we have generated a codon-optimized
hGagp17p24–Polp51 plasmid DNA expressing the Gag–Pol
fusion protein consisting of clusters of highly conserved
epitopes presented by multiple MHC class I alleles. In this
construct, the ribosomal frameshift site has been deletedtogether with the potentially immunosuppressive Gag
nucleocapsid as well as Pol protease and integrase. The
gag-encoded nucleocapsid was removed, as this antigen
contains functionally important features such as the zinc
finger domain, the p7/p1 protease cleavage site of Gag, and
the Vpr binding sites in p6 (Yu et al., 2002), which may
prove undesirable as a component of therapeutic vaccines.
Another deletion included the pol-encoded protease gene
due to the potential cytotoxic effect of the active viral
protease and its possible inhibition of the transgene
expression level (Huang et al., 2001; zur Megede et al.,
2003). Additionally, the integrase was removed to avoid
possible integration of vaccine sequences into the host
genome (Hehl et al., 2004; Parissi et al., 2001). The Pol p51
domain was extended at the C-terminus to alter its three-
dimensional structure and include CTL epitopes that are
between the reverse transcriptase (RT)/RNase H (RH) region
in the Gag–Pol precursor protein (Korber et al., 2003).
We showed that the specific modifications introduced in
the hGagp17p24–Polp51 construct increased intracellular
expression of the Gag–Pol fusion protein, which was
associated with induction of enhanced immune responses
and protection against challenge with Gag- and Pol-
expressing recombinant vaccinia viruses (rVVs) compared
to responses elicited with the full-length hGag–PolDFsDPr
vaccine. The results presented in this study indicate that
immune responses against the conserved epitopes within the
Gag–Pol cassettes could be enhanced through removal of
the ribosomal frameshift site and deletion of regulatory
regions with possible immunosuppressive effects on expres-
sion and immunogenicity of the transgene.Results
In vitro characterization of the hGagp17p24–Polp51 fusion
protein construct
To increase the immunogenicity of the Gag–Pol fusion
protein vaccine, we have generated the hGagp17p24–
Polp51 construct that contains domains with the highest
density of conserved CTL and Th epitopes. The
hGagp17p24–Polp51 construct expressed in a rev-inde-
pendent fashion consists of highly immunogenic gag p17
and p24 genes fused-in-frame with a modified pol p51
sequence (Fig. 1A). The Pol p51 fragment was extended at
the C-terminus by an additional 16-amino acid sequence
(YVDGAANRETKLGKAG) of the RH domain that con-
tains five CTL epitopes (Korber et al., 2003). Direct
sequence analysis of the hGagp17p24–Polp51 construct
confirmed the presence of an open reading frame corre-
sponding to Gag p17 and p24 antigens as well as the 16
amino acid-extended Pol p51 protein. Based on the HIV
Molecular Immunology Database (Korber et al., 2003), the
Gag p17 and p24 antigens harbor 348 conserved CTL
epitopes presented by multiple MHC class I alleles that are
Fig. 1. Expression of Gag–Pol fusion proteins by the hGagp17p24–Polp51 and hGag–PolDFsDPr constructs. (A) Schematic representation of HIV-1 gag–pol
expression constructs. The gag p17, 24, and pol p51 sequences from the synthetic hGag–PolDFsDPr gene (Huang et al., 2001) were used to create the
hGagp17p24–Polp51 expression vector based on human (h) codon usage. (B) Expression of HIV-1 Gag–Pol fusion proteins in cells transfected with the hGag–
PolDFsDPr and hGagp17p24–Polp51 genes. 293T cells were transfected with plasmid DNA encoding the hGag–PolDFsDPr or hGagp17p24–Polp51 fusion
protein. Control cells were transfected with the backbone plasmid. The transfected cells were labeled with [35S]methionine/cysteine and analyzed for
expression of the Gag–Pol fusion proteins in cell lysates and supernatants by immunoprecipitation with human anti-HIV-1 IgG. Immunoprecipitates from cell
lysates (lanes C) and supernatants (lanes S) of control, hGag–PolDFsDPr, and hGagp17p24–Polp51 transfectants were separated on a NuPAGEk 4–12% Bis-
Tris Gel. (C). Intracellular expression of Gag p24 antigen was determined in cell extracts prepared from 293T cells transfected with plasmid DNA encoding the
hGag–PolDFsDPr or hGagp17p24–Polp51 fusion protein using the HIV-1 p24 antigen capture assay. Control cells were transfected with the sham vector. For
the analysis of intracellular expression of Gag, the cells were harvested 24, 48, and 72 h after transfection. The respective expression levels of Gag protein in
cell extracts prepared from hGagp17p24-Polp5- and hGag–PolDFsDPr-transfected cells 24, 48, and 72 h after transfection were 17.8F 3.5 vs. 4.2F 0.8 ng/ml;
15.8 F 4.2 vs. 3.2 F 0.6 ng/ml; and 5.1 F 1.9 vs. 1.3 F 0.2 ng/ml.
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contain 44 Th epitopes presented by multiple MHC class II
determinants. The extended Pol p51 domain consists of four
immunogenic clusters that harbor 146 CTL and 35 Th
epitopes (Table 1).
To compare the expression of the modified hGagp17p24–
Polp51 and full-length hGag–PolDFsDPr fusion proteins,
culture supernatants and lysates from 293T cells transiently
transfected with the respective constructs were analyzed by
immunoprecipitation with human anti-HIV-1 IgG. As shown
in Fig. 1B, the full-length Gag–Pol p160 protein was
detected in lysates prepared 48 h after transfection from
cells expressing the hGag–PolDFsDPr fusion protein. In
extracts prepared from cells transfected with thehGagp17p24–Polp51 plasmid, a prominent band of approx-
imately 92 kDa was precipitated with the HIV-1-specific
IgG. This band corresponded to the fusion protein consisting
of Gag p17, p24, and Pol p51 polypeptides, and was also
precipitated with specific mAbs (data not shown). The
intensity of the band corresponding to the hGagp17p24–
Polp51 fusion protein was approximately 4-fold higher than
that of the full-length hGag–PolDFsDPr protein as deter-
mined by densitometry. As expected, lysates from 293T cells
transfected with the backbone plasmid did not contain a band
corresponding to the fusion protein. Additionally, no pellet-
able form of the fusion protein could be detected in culture
supernatants derived from hGag–PolDFsDPr- or
hGagp17p24–Polp51-transfected 293T cells that indicated
Table 1
Maps of CTL epitope clusters within the Gag–Pol region
Clusters of CTL epitopesa Epitope
numbers
Restricting elements of CTL epitopesb
Gag p17 aa 10–50 36 B*4002, B62, A3, A3.1, B27, B*0301, B*2705, A03, A*0301, A30, B42, Bw62, B8, Cw4, B7, B*0801,
A*2402, A23, A24, B*3501, B35
Gag p17 aa 71–105 35 A2, A02, A30, B8, A1, B*0801, A*3002, A*0202, A*0205, A*0214, A*0201, A2.1, B*0201, B62,
HLA-A201, A11, A*1101, B*4001, B60
Gag p24 aa 7–150 202 B57, Cw3, B14, A3 supertype, A*2501, A25, A5, B*5701, B*5801, B*0702, B7, B07, B*8101, A2, A*02,
A*0202, B*4415, B27, B*8101, B*5703, B58, A*2601, A26, C*0102(Cw1), Cw*0102, Cw1, B12, B44,
B42, B*4001, B60, B61, A*4201, B*5301, B42, B53, C*0802(Cw8), Cw8, B*1402, B*1510, B*3901, B38,
B39, B52, H-2d, H-2hd, B*4002, B55, B*5801, B8, B*3501, B35, B8, B*0801, A*2402, B27, B62, Part-B*03,
B*2703, B*2705, A33, Bw62, B62, B*1501, B*5201, B52
Gag p24 aa 159–230 75 H-2d, B*4031, B*1801, B18, B71, A*2402, A24, B*4402, B44, A26, B70, A*0207, B*1510, Cw*0303,
Cw*0304, B*1402, B14, B*1402, B57, Cw8, B*4402, Cw*05, B*5301, B*5701, B53, Cw4, B8, B51, B*5101,
B51, B8, B35, B*0801, A2, B7, A*1101, A11
RT aa 91–148 27 A3, Cw4, B*3501, B35, A*0201, A2, B*5101, B24, A11, A*02, A*0217, B*5101, B51, A2 supertype
RT aa 151–220 51 B*5101, B7, B*3501, B35, A*0301, A11, A33, A3, A3.1, A*6801, B*0301, A*3002, B51, A*0201, A2,
A*0202, A2.1, B51, B58, B*4001, B60, B61, B44, A3 supertype
RT aa 240–320 53 B*5701, B57, B*5801, B*1501, Bw62, A*3002, A30, A*1101, A3, B*4201, B42, B*3501, B*5101, B*5301,
B*0702, B35, B51, A*0201, A*02, A*0205, A2, A*0202, A2.1, A2 supertype, B62
RT aa 356–545 15 A2, A2.1, B14, B*1503, B*1402, Cw8, B7, A*1101, A*0301, A3 supertype
a The immunogenic regions of the HIV-1 Gag and Pol proteins have been determined by the presence of at least 15 CTL epitopes with multiple HLA class I-
binding motifs based on the HIV Molecular Immunology 2003 database.
b The HLA-presenting molecules have been determined at the serotype and the genotype levels.
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observation was also confirmed by electron microscopic
analysis (data not shown).
The increase in the relative expression level of the
hGagp17p24–Polp51 fusion protein over that of the full-
length hGag–PolDFsDPr counterpart was further determined
by measuring the level of Gag protein in cell extracts
prepared from 293T cells transfected with the hGagp17p24–
Polp51 or hGag–PolDFsDPr construct. Lysates prepared
from cells transfected with the sham vector served as
negative control. The analysis was carried out 24, 48, and 72
h after transfection using the HIV-1 antigen capture assay.
Serial dilutions of cell extracts revealed differences in the
level of Gag protein expression in cultures transfected with
hGagp17p24–Polp51 and hGag–PolDFsDPr constructs. As
shown in Fig. 1C, the intracellular level of Gag was 4- to 5-
fold higher in lysates derived from hGagp17p24–Polp51-
transfected cells than those expressing the hGag–PolDFsDPr
fusion protein (P b 0.001). Since no p24 protein was
detected in supernatants harvested from transfected cultures,
the observed differences in the intracellular Gag expression
could be attributed to increases in protein synthesis in cells
expressing the hGagp17p24–Polp51 fusion protein com-
pared to those transfected with the full-length hGag–
PolDFsDPr counterpart.
CTL responses induced by the hGagp17p24–Polp51 and
hGag–PolDFsDPr vaccines
As CD8+ T lymphocytes are considered the most crucial
components of antiviral effector cell responses, we com-
pared the ability of the hGagp17p24–Polp51 and hGag–
PolDFsDPr vaccines to induce CTL responses againsthighly conserved Gag- and Pol-specific peptides in HLA-
A2/Kb transgenic mice. The transgenic mice (n = 6) were
immunized intramuscularly (im) with plasmid DNA
expressing either the hGagp17p24–Polp51 or hGag–
PolDFsDPr fusion protein, and analyzed for the frequency
of IFN-g-secreting CD8+ T cells in splenocytes stimulated
with HLA-A2-restricted Gag p17-, p24-, and Pol RT-
specific peptides (Korber et al., 2003). To augment the
specific responses, 20 Ag of plasmid DNA encoding IL-
12p40 and IL-12p35 was coadministered im with the
specific vaccine (Kiszka et al., 2002). The Gag-specific
peptides used for stimulation consisted of (i) p17-specific
peptide 17A, aa 77–85 (SLYNTVATL) with consensus for
HIV-1 group M and subtypes A, B, C, D, and G; and (ii)
p24-specific peptide 24D, aa 19–27 (TLNAWVKVI) with
consensus for subtypes B, G, and H (Korber et al., 2002).
The RT-specific peptides consisted of (i) peptide 51F aa
179–187 (VIYQYMDDL) with consensus for HIV-1 group
M and subtypes B, C, D, and G; and (ii) peptide 51H aa
485–495 (ALQDSGSEVN) with consensus for subtypes B,
D, and H (Korber et al., 2002).
Fig. 2 shows that the HLA-A2/Kb transgenic mice
immunized with the hGagp17p24–Polp51 vaccine exhibited
2- to 5-fold higher responses to the p17-, p24-, and RT-
specific peptides than animals immunized with the full-
length hGag–PolDFsDPr construct, with the highest reac-
tivity directed to peptides 17A and 51F. The numbers of
IFN-g-secreting CD8+ T cells specific for peptides 17A and
51F were 2-fold higher in mice immunized with the
hGagp17p24–Polp51 construct than the hGag–PolDFsDPr
counterpart (P b 0.05). In mice immunized with the
hGagp17p24–Polp51 construct, responses to peptides 51H
and 24D were 3- and 5-fold higher than those for the hGag–
Fig. 2. Cellular responses to Gag p17-, p24-, and Pol RT-specific peptides
in HLA-A2/Kb mice immunized with the hGagp17p24–Polp51 and hGag–
PolDFsDPr vaccines. The number of IFN-g-secreting CD8+ T cells in Gag
p17, p24, and Pol RT peptide-stimulated splenocytes from the immunized
mice was determined by ELISPOT. The HLA-A2-restricted Gag and Pol
peptides included p17-specific peptide 17A, aa 77–85 (SLYNTVATL), p24-
specific peptide 24D, aa 19–27 (TLNAWVKVI), and RT-specific peptides
51F aa 179–187 (VIYQYMDDL) and 51H aa 485–495 (ALQDSGSEVN).
The HLA-A2-restricted Env-specific peptide D1, aa 121–129
(KLTPLCVTL) was used as a control. The frequencies of IFN-g-secreting
cells were determined by regression analysis from a curve generated by
plotting the number of spots vs. the number of effector cells. Results are
presented as the means F SD of at least three independent experiments.
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respectively). In the latter group of mice, the numbers of
IFN-g-secreting CD8+ T cells stimulated with peptide 24D
were comparable to those measured in control cultures
stimulated with the envelope (Env) peptide D1, aa 121–129
(KLTPLCVTL).
The enhancement of T-cell responses to the conserved
p17-, p24-, and RT-specific CTL peptides after immuniza-
tion with the hGagp17p24–Polp51 vaccine was further
examined in the standard 51Cr-release assay against Jurkat-
A2/Kb cells infected with rVVs expressing Gag (vAbT141)Fig. 3. Analysis of CTL responses to peptides 17A, 24D, 51F, and 51H in HLA-A
vaccines. Splenocytes from HLA-A2/Kb mice immunized with the hGagp17p24–P
stimulated with the 17A, 24D, 51F, or 51H peptides for 6 days and analyzed for
vAbT204-infected Jurkat-A2/Kb cells. The effector-to-target cell ratio was 12:1
determinations were made in triplicate samples with SD b10%. Results are preseand Pol (vAbT204) antigens. Splenocytes from the HLA-A2/
Kb transgenic mice, vaccinated either with hGagp17p24–
Polp51 or hGag–PolDFsDPr, were stimulated for 6 days with
peptide 17A, 24D, 51F, or 51H for the assessment of specific
cytotoxic activities. At an effector-to-target ratio of 12:1,
cultures derived from mice immunized with the
hGagp17p24–Polp51 vaccine and stimulated with peptides
17A and 51F exhibited roughly 2-fold increases in lysis of
Jurkat-A2/Kb cells expressing gag or pol gene products
compared to responses induced with the hGag–PolDFsDPr
vaccine (Fig. 3). A similar but less pronounced effect was
observed for the 24D and 51H peptides.
Protection against challenge with rVVs expressing Gag and
Pol antigens
The significance of the hGagp17p24–Polp51 and hGag–
PolDFsDPr vaccine-induced CD8+ T cell-mediated immune
responses was further examined in protective studies against
challenge with vAbT141 and vAbT204 as surrogates for
HIV-1 (Belyakov et al., 1998). The HLA-A2/Kb transgenic
mice immunized with the hGagp17p24–Polp51 or hGag–
PolDFsDPr construct coadministered with IL-12-encoded
plasmid DNAwere challenged on day 28 with 5  106 PFU
of vAbT141 or vAbT204 virus delivered intraperitoneally
(ip) as described (Kiszka et al., 2002). To determine whether
any protection induced by vaccination with the Gag–Pol
fusion protein constructs was specific, additional groups of
hGagp17p24–Polp51- or hGag–PolDFsDPr-immunized and
control mice were challenged with h-galactosidase-express-
ing vSC8 virus. Because the vaccinia virus replicates most
efficiently in ovaries (Belyakov et al., 1998), ovaries were
removed 5 days after challenge and tested for viral titers on
a monolayer of HuTK 143B cell line.
As shown in Fig. 4, the vaccinia titers in ovaries of mice
immunized with the hGagp17p24–Polp51 and hGag–2/Kb mice immunized with the hGagp17p24–Polp51 and hGag–PolDFsDPr
olp51 (black bars) and the hGag–PolDFsDPr construct (hatched bars) were
the CTL activity in a standard 4-h 51Cr-release assay against vAbT14- or
. Control cultures were stimulated with the Env-specific peptide D1. All
nted as the means F SD of three independent experiments.
Fig. 4. Protection against challenge with rVV-expressing gag and pol gene
products induced by the hGagp17p24–Polp51 and hGag–PolDFsDPr
vaccines. The HLA-A2/Kb transgenic mice were immunized with the
hGagp17p24–Polp51, hGag–PolDFsDPr, or backbone plasmid and chal-
lenged ip with 5 106 PFU of vAbT141, vAbT204, or vSC8 on day 28 after
the last immunization. Five days later, mice were sacrificed, ovaries were
removed, homogenized, sonicated, and assayed for vaccinia virus titer by
plating serial 10-fold dilutions on human HuTK 143B cells, staining with
crystal violet, and counting plaques at each dilution. The rVV titers are
presented as the mean log10F SD of PFU per ovaries of four mice per group.
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either gag or pol gene products were approximately 100- to
10000-fold lower compared with responses measured in the
control group of mice. Immunization with the hGagp17p24–
Polp51 construct induced approximately 100-fold higherFig. 5. Gag p24- and Pol RT-specific cytokine responses in BALB/c mice immuniz
of Gag p24- and Pol RT-specific IL-2 (A), IFN-g (B), and IL-4 (C) responses in s
measured by ELISA 4 weeks after specific vaccination. Results are presented asprotection against challenge with Gag protein-expressing
vAbT141 virus than vaccination with hGag–PolDFsDPr (P =
0.003). The protective responses against challenge with
vAbT204-expressing pol gene products in hGagp17p24–
Polp51-immunized mice were approximately 10-fold higher
than those induced by the hGag–PolDFsDPr vaccine (P =
0.02). The lack of differences between vaccinia virus titers in
the ovaries of control and immunized mice challenged with
the h-galactosidase-expressing vSC8 virus indicated that the
reduction in viral titers in mice immunized with the
hGagp17p24–Polp51 and hGag–PolDFsDPr vaccines could
not be mediated by nonspecific inflammatory responses.
Cytokine production in immunized mice
The finding that HIV-1 Gag p24-specific Th responses
inversely correlate with viral burden in HIV-1-infected
individuals (Imami et al., 2002; Rosenberg et al., 1997)
prompted us to examine the profile of cytokine responses
induced by the hGagp17p24–Polp51 and hGag–PolDFsDPr
vaccines. Groups of BALB/c mice (n = 4) were immunized
im on days 0, 14, 28, and 42 with the hGagp17p24–Polp51
or hGag–PolDFsDPr vector, and the level of IL-2, IFN-g,
and IL-4 was measured in supernatants from splenocyte
cultures stimulated for 72 h with the p24 or RT recombinant
protein. Figs. 5A and B show increases in IL-2 and IFN-g
levels in p24-stimulated cultures from hGagp17p24–ed with the hGagp17p24–Polp51 and hGag–PolDFsDPr vaccines. The levels
plenocyte cultures stimulated with the p24 or RT recombinant protein were
the means F SD of at least three independent experiments.
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from animals vaccinated with the hGag–PolDFsDPr con-
struct (P = 0.005 and P = 0.011, respectively). The RT-
specific IL-2 and IFN-g responses were also augmented in
mice immunized with the hGagp17p24–Polp51 (P = 0.023
and P = 0.07, respectively; Figs. 5A and B), whereas IL-4
responses were low and at comparable levels in both groups
of vaccinated mice (Fig. 5C).
Gag- and Pol-specific antibody responses in mice
immunized with the hGagp17p24–Polp51 and
hGag–PolDFsDPr vaccines
Next, we measured p24- and RT-specific antibody
responses in sera from mice immunized with plasmids
encoding the hGagp17p24–Polp51 and hGag–PolDFsDPr
fusion proteins. In both groups of immunized mice, we
detected higher IgG than IgM antibody responses against
p24 (Figs. 6A and B) and RT (Figs. 7A and B) proteins.
Analyses of IgG subisotypes revealed a comparable level of
p24- and RT-specific IgG2a, IgG1 antibody responses (Figs.
6C and 7C). However, the p24-specific IgG2b antibody titer
was approximately 10-fold higher in sera of mice immu-
nized with the hGagp17p24–Polp51 than the hGag–
PolDFsDPr vaccine (1:1000 vs. 1:100) (Fig. 6C). Similarly,Fig. 6. Gag p24-specific antibody responses induced by vaccination of BALB/c
titers of Gag p24-specific IgG (A) and IgM (B) antibody responses as well as IgG
using alkaline phosphatase-conjugated secondary antibodies. Results are expre
experiments including four mice per group.the end-point titer of RT-specific IgG2b antibody responses
induced by the hGagp17p24–Polp5 vaccine was at least 3-
fold higher than that measured in hGag–PolDFsDPr-immu-
nized mice (Fig. 7C).Discussion
Clinical trials of candidate AIDS vaccines have con-
firmed that in order to ensure a broad immune response, an
effective vaccine may have to express multiple HIV-1
proteins and induce both cellular and humoral responses
with a large repertoire of specificities (Borrow et al., 1994;
Haas et al., 1998; Rowland-Jones et al., 1998; Wasik et al.,
1999). While the development of the first generation of
HIV-1 vaccines was primarily focused on induction of
neutralizing antibodies using HIV-1 Env, recent efforts have
been extended to the induction of cellular responses to
conserved CTL and Th epitopes located within the Gag and
Pol antigens to provide protection against genetically
diverse viral quasispecies. Additionally, because successful
HIV-1 vaccines would likely be composed of several
antigens, the ability to effectively express experimentally
defined HIV-1 epitopes concentrated in relatively conserved
regions might be of significant importance (Kong et al.,mice with the hGagp17p24–Polp51 and hGag–PolDFsDPr constructs. The
subclasses (C) in sera of the immunized mice were determined by ELISA
ssed as absorbance at 405 nm and presented as mean values F SD of
Fig. 7. RT-specific antibody responses induced by vaccination of BALB/c mice with the hGagp17p24–Polp51 and hGag–PolDFsDPr constructs. The titers of
RT-specific IgG (A) and IgM (B) antibody responses as well as IgG subclasses (C) in sera of the immunized mice were determined by ELISA. Results are
presented as are expressed as absorbance at 405 nm, and presented as mean values F SD of experiments including four mice per group.
E. Bolesta et al. / Virology 332 (2005) 467–4794742003; Korber et al., 2003). Previously, we and others have
reported that by removal of the natural frameshift site in the
mRNA corresponding to Gag–Pol, it was possible to
increase Pol expression and induce stronger Pol-specific
immune responses than those elicited by the native Gag–
Pol gene (Huang et al., 2001; Kmieciak et al., 2001; zur
Megede et al., 2003). However, issues relevant to the
optimal expression of highly conserved epitopes that are
clustered within the Gag and Pol domains have not been
extensively explored.
In these studies, we analyzed whether inclusion of short
regions consisting of clusters of epitopes together with
proximal sequences in the hGagp17p24–Polp51 fusion
protein construct would induce Gag- and Pol-specific
cellular responses to CTL epitopes with consensus sequen-
ces for multiple HIV-1 subtypes. Using the same expression
system and strains of mice, we showed that the
hGagp17p24–Polp51 construct was more effective in stim-
ulating Gag- and Pol-specific immune responses than the
full-length counterpart. The profile of CD8+ T cell responses
was also consistent with results of the challenge studies,
which demonstrated increased protection against rVV
expressing either gag or pol gene products in mice immu-
nized with the hGagp17p24–Polp51 than the full-length
hGag–PolDFsDPr counterpart. Because the vaccinia virus
does not incorporate the Gag or Pol protein in the virion but
expresses it only in infected cells, the protection was
mediated by specific CTL rather than antibody responses.The detection of an increased level of immune responses
in mice immunized with the hGagp17p24–Polp51 than the
hGag–PolDFsDPr vaccine could be attributed to differences
in the expression level of the intracellular Gag–Pol fusion
proteins. Because the hGagp17p24–Polp51 fusion protein
consists of clusters of epitopes, higher expression of this
construct would augment the pool of Gag- and Pol-specific
CTL and Th epitopes available for presentation in immu-
nized mice. Previous results have demonstrated that the
magnitude of epitope-specific CTL responses is correlated
with the expression level of the corresponding class I
molecule–peptide complex on the surface of infected cells
(Gallimore et al., 1998). In view of these findings, it is
possible that the increased CTL responses to gag and pol
gene products in hGagp17p24–Polp51-vaccinated mice
could be due to the higher number of conserved epitopes
available for presentation than in animals immunized with
the full-length hGag–PolDFsDPr construct.
The concept of removal of potentially immunosuppres-
sive HIV-1 genes has been explored in vaccine strategies
against AIDS with attenuated viruses (Bogers et al., 1995).
Although the live-attenuated vaccine approach was found to
be effective, concern for safety is the key factor that requires
further evaluation of such vaccines for use in humans (Baba
et al., 1995; Belshe et al., 1994; Wyand et al., 1997). Other
attractive strategies for HIV-1 vaccine design are based on
polytope genetic vaccines consisting of several CTL
epitopes (Woodberry et al., 1999) or vaccines based on a
E. Bolesta et al. / Virology 332 (2005) 467–479 475mixture of multiepitopic peptides corresponding to regu-
latory or structural HIV-1 antigens (Gahery-Segard et al.,
2000). Although these vaccines are also aimed at inducing
immunity to selected regions that are highly conserved, it
remains unclear whether responses to few epitopes are
sufficient for biologically significant immunity in humans.
The observed immunological correlation with epitope
clustering favors an alternative way to design polyepitope
Gag–Pol vaccines by inclusion of short regions where
epitopes cluster together with the proximal regions, rather
than a string of single epitopes. Like a polyepitope string,
these short regions might be safer than the full-length
protein and would facilitate the inclusion of cocktails of
variants. Furthermore, these regions contain overlapping
epitopes presented by multiple HLA molecules, and natural
processing signals of known epitopes might also be
included to maximize the magnitude and breadth of specific
immune responses.Materials and methods
Construction of hGagp17p24–Polp51 expression vector
The recombinant plasmid encoding the hGagp17p24–
Polp51 fusion protein consisting of Gag p17, p24, and Pol
p51 regions was prepared from the synthetic hGag–
PolDFsDPr gene (Huang et al., 2001). The hGag–
PolDFsDPr vector was kindly provided by Dr. Gary Nabel
(National Institute of Allergy and Infectious Diseases, NIH,
Bethesda, MD). For the generation of the hGagp17p24–
Polp51 construct, two fragments corresponding to Gag
p17p24 (amino acids 1–363) from HXB2 (GenBank
accession no. K03455) and modified Pol p51 (amino acids
1–456) from NL4-3 (GenBank accession no. M19921) were
synthesized by PCR with Turbo Pfu high fidelity DNA
polymerase (Strategene, La Jolla, CA). The gag p17p24
gene was synthesized with primer A (5V-ATCGTCGACATQ
GGCCGCCCGCGCCCGCATGGGCGCCCGCGCCGC-3V)
containing the SalI cleavage site together with anti-sense
primer B (5V-CACGCGAAGCTTGTGGCCGGGGCCGCC-
3V) containing the HindIII restriction site. The nucleotide
sequences for the restriction enzyme cleavage sites are
underlined. To ensure a cytoplasmic expression of the
hGagp17p24–Polp51 fusion protein, an oligonucleotide
linker that destroys the myristylation signal in the HIV-1
Gag molecule was inserted upstream of the gag start codon
(Qiu et al., 2000).
The modified pol p51 gene was synthesized with primer
C that contains the HindIII restriction enzyme site (5V-
GGCCACAAGCTTCGCGTGCTGCCCATCAGCCC-
CATCGAG-3V) in conjunction with the anti-sense primer
D (5 V-TATGAATTCGCGGCCGCCTAGGCCTTG
CCCAGCTTGGTC-3) containing the EcoRI and NotI sites
followed by a stop codon. The Pol p51 protein was extended
by the amino acid YVDGAANRETKLGKAG sequencecorresponding to the N-terminal region of RH to include
CTL epitopes that are present in the Gag–Pol precursor
protein. For ligation, the gag p17p24 gene was digested with
SalI and HindIII, and the p51 fragment was digested with
HindIII and EcoRI enzymes. Both fragments were ligated
together and cloned into SalI and EcoRI restriction sites of
the pVRC 4000 expression vector (Huang et al., 2001).
Transfection, labeling, and immunoprecipitation
Transient transfection of 293T cells was performed by
calcium phosphate precipitation with 50 Ag of plasmid DNA
encoding the hGagp17p24–Polp51 or hGag–PolDFsDPr
fusion protein. Control cells were transfected with the
backbone plasmid. For radioimmunoprecipitation, [35S]me-
thionine/cysteine (400 ACi/plate; DuPont-New England
Nuclear, Boston, MA) was added on the second day of
transfection for an additional 24-h period. At the end of the
incubation period, the cells were pelleted and lysed using
Nonidet P-40 buffer (0.5%Nonidet P-40, 0.5MNaCl, and 10
mM Tris–HCl [pH 7.5]). Equal amounts of radiolabeled cell
lysates, based on the protein concentration, were immuno-
precipitated with human anti-HIV-1 IgG (Kmieciak et al.,
2001) followed by polyclonal rabbit antihuman Ig (ICN
Biomedicals, Inc., CostaMesa, CA) and protein A-Sepharose
CL-4B (Pharmacia Biotech, Piscataway, NJ). Culture super-
natants from transfected cells were harvested, precleared by
centrifugation at 16000  g, and concentrated by centrifu-
gation through a 20% sucrose cushion at 100000 g for 2 h
in a Beckman ultracentrifuge. The pellet was lysed in Nonidet
P-40 buffer and incubated with human anti-HIV-1 IgG
followed by polyclonal rabbit antihuman Ig and protein A-
Sepharose CL-4B. Immunoprecipitates were separated on a
NuPAGE 4–12% Bis-Tris Gel. The gels were fluorographed
to visualize [35S]methionine/cysteine-labeled proteins, and
the intensity of individual bands was quantified with a
LabImage version 2.62 (Copyright 1999–2001, Kapelan
GmbH).
Analysis of Gag protein expression
Transient transfection of 293T cells was performed by
calcium phosphate precipitation with 50 Ag of plasmid
DNA encoding the hGag–PolDFsDPr or hGagp17p24–
Polp51 fusion protein. Control cells were transfected with
the backbone plasmid DNA. The cells were harvested 24,
48, and 72 h after transfection to measure the level of Gag
p24 protein expression. The cell pellets were lysed in a
total volume 1 ml of 0.5% Nonidet P-40/PBS and
centrifuged to remove cellular debris. The expression of
Gag in cell lysates was quantified by the p24 antigen
capture assay (NEN Life Science Products, Inc., Boston,
MA) according to the manufacturer’s protocol. The total
protein concentration in cell lysates was determined by
Bradford assay (Bio-Rad, Hercules, CA) according to the
manufacturer’s protocol.
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The HLA-A2-restricted, Gag-specific peptides (peptide
17A, aa 77–85 [SLYNTVATL] and peptide 24D, aa 151–
159 [TLNAWVKVV]) and Pol RT-specific peptides (pep-
tide 51F, aa 179–187 [VIYQYMDDL] and peptide 51H,
[ALQDSGSEVN]) as well as the control Env peptide
(peptide D1, aa 121–129 [KLTPLCVTL]) have been
previously described (Korber et al., 2003). All peptides
were synthesized using 9-fluorenylmethoxy carbonyl meth-
odology, purified by reverse-phase high-performance liquid
chromatography, and characterized by amino acid analysis
and laser desorption mass spectroscopy at the Wistar
Institute (Philadelphia, PA).
Mice and immunization
The HLA-A2/Kb transgenic mice, expressing hybrid
molecules bearing the a1 and a2 domains of HLA-A2.1
fused to the a3 domain of H-2Kb, were provided by Dr. L.
Sherman (The Scripps Research Institute, San Diego, CA).
Six-week-old BALB/c (H-2d) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). All mice were
maintained in a specific pathogen-free microisolator envi-
ronment. Groups of six HLA-A2/Kb transgenic mice and
four BALB/c mice were injected im in the quadriceps with
100 Ag of plasmid DNA encoding the hGag–PolDFsDPr or
hGagp17p24–Polp51 fusion protein on days 0, 14, 28, and
42. Mice immunized with the backbone plasmid were used
as controls. To augment the specific responses, 20 Ag of
plasmid DNA encoding IL-12p40 and IL-12p35 (Kaufman
et al., 1991) was administered im at the time of specific
vaccination.
In vitro stimulation assay
The level of p24- and RT-specific IFN-g, IL-2, and
IL-4 responses in splenocytes of immunized BALB/c
mice was analyzed 4 weeks after the specific vaccination.
Splenocyte cultures (3  106 cells/ml) were incubated in
96-well plate (Linbro, ICN Biomedicals Inc., Aurora,
OH) with 3 Ag/ml of p24 or RT recombinant protein
(Immunodiagnostics Inc., Woburn, MA), or with medium
only. On the third day of stimulation, culture super-
natants were collected and analyzed for IFN-g, IL-2, and
IL-4 production by ELISA (Quantikine, R&D Systems,
Minneapolis, MN) according to the manufacturer’s
protocol.
Vaccinia viruses
The rVVs expressing the full-length Gag of HIV-1BH10
(vAbT141) and Pol HIV-1HXB2 (vAbT204) (Luzuriaga et
al., 1995) were provided by Dr. G. Mazzara (Therion
Biologicals, Cambridge, MA). The rVV-expressing h-
galactosidase (vSC8) (Earl et al., 1991) was provided byDr. B. Moss (Laboratories of Viral Diseases, National
Institute of Allergy and Infectious Diseases, NIH, Bethesda,
MD).
ELISPOT assay
The number of IFN-g-secreting T cells specific for Gag
p17-, p24-, and Pol RT-specific peptides in splenocytes of
HLA-A2/Kb transgenic mice was determined by the
ELISPOT method (Miyahira et al., 1995) 3 weeks after
the last immunization. Briefly, 96-well nitrocellulose plates
(Millipore multiscreen-MAIP, Millipore, Bedford, MA)
were coated with 15 Ag/ml of rat anti-mouse mAb directed
to IFN-g (MAB785, R&D Systems Inc.) in carbonate-
bicarbonate buffer pH 9.6 (Sigma, St. Louis, MO). After
overnight incubation at 4 8C, the wells were washed with
PBS containing 0.05% Tween 20 and blocked for 1 h with
RPMI 1640 medium containing 10% FCS. Splenocytes
from immunized mice were resuspended to 107 cells/ml
and placed in 2-fold dilutions into the antibody-coated
wells in the presence of a 1 AM concentration of the p17-,
p24-, and RT-specific or control peptides. For each dilution
duplicate samples were used. After 24 h of incubation at
37 8C, the plates were washed six times with PBS
containing 0.05% Tween 20 and incubated for 2 h with
50 Al of 1 Ag/ml of biotinylated mAb directed to mouse
IFN-g (MAB485, R&D Systems Inc.). The plates were
washed and incubated for 1 h with 50 Al of 1:1000 diluted
streptavidin-conjugated alkaline phosphatase (SA-5100,
Vector Laboratories, Inc., Burlingame, CA). After final
wash with PBS, spots were developed with an alkaline
phosphatase BCIP/NBT (5-bromo-4-chloro-3-indolyl-1-
phosphate/nitro blue tetrazolium) substrate (SK-5400,
Vector Laboratories, Inc.) and counted under a stereo-
microscope. The frequencies of IFN-g-secreting cells were
determined by regression analysis from a curve generated
by plotting the number of spots vs. the number of effector
cells.
Cytotoxicity assay
Cytotoxic activity of Gag p17, p24, and Pol RT
peptide-specific CTL lines established from splenocytes
of HLA-A2/Kb-immunized mice was analyzed after 6
days of cultures in a standard 4-h 51Cr-release assay
against Jurkat-A2/Kb cells (human T-cell leukemia line
transfected with the chimeric construct A2/Kb, provided
by Dr. L. Sherman) infected with vAbT141 or vAbT204.
Control target cells were infected with vSC8. The percent-
specific lysis was calculated as: ([cpm experimental
release  cpm spontaneous release] / [cpm maximum
release  cpm spontaneous release])  100. Maximum
release was determined from supernatants of cells that
were lysed by addition of 5% Triton X-100. Spontaneous
release was determined from target cells incubated with
medium only.
E. Bolesta et al. / Virology 332 (2005) 467–479 477Measurement of anti-p24 and anti-RT antibody titers and
isotypes
The level of p24- and RT-specific antibodies was
determined by testing serial 2-fold dilutions of sera from
immunized mice by ELISA. Briefly, 96-well ELISA
Maxisorp plates (Nunc, Naperville, IL) were coated over-
night with 3 Ag/ml of Gag p24 or RT recombinant protein
(Immunodiagnostics Inc.) in carbonate-bicarbonate buffer
pH 9.6 (Sigma). Following a wash with PBS containing
0.05% Tween 20 (PBS/Tween 20), the wells were blocked
for 2 h with a solution containing 2% BSA (Sigma) and
0.05% Tween 20 in PBS. Sera were prepared from murine
blood samples, serially diluted in PBS/Tween 20, and added
to the wells. For each dilution, duplicate wells were used.
After 1-h incubation at room temperature, the plates were
washed three times and incubated with a 1/500 dilution of
alkaline phosphatase-conjugated goat anti-mouse IgG or
IgM (Sigma) in PBS/Tween 20. Subisotyping of serum IgG
antibody responses in immunized mice was carried out with
alkaline phosphatase-conjugated rat anti-mouse IgG1,
IgG2a, IgG2b, or IgG3 secondary antibodies (BD PharMin-
gen, San Diego, CA). After washing, the reaction was
developed with p-nitrophenylphosphate (1 mg/ml; Bio-Rad
Laboratories) in diethanolamine buffer (BIO-RAD), stopped
with 0.4 M NaOH, and analyzed at 405 nm with an ELISA
plate reader. Sample dilutions were considered positive if
the optical density recorded for that dilution was at least 2-
fold higher than the optical density recorded for the control
sample at the same dilution (Staats et al., 1996).
Protection against challenge with rVVs expressing Gag and
Pol proteins
On day 28 after the last immunization with the
hGagp17p24–Polp51 and hGag–PolDFsDPr vaccines, mice
were challenged ip with 5  106 PFU of vAbT141,
vAbT204, or vSC8. Five days later, mice were sacrificed,
ovaries removed, homogenized, sonicated, and assayed for
vaccinia virus titer by plating serial 10-fold dilutions on
human HuTK 143B indicator cells, staining with crystal
violet, and counting plaques at each dilution.
Data analysis
The significance of differences in the numbers of p17,
p25, and RT peptide-specific IFN-g-secreting CD8+ cells,
and the levels of Gag p24- and RT-specific cytokine
production induced by the Gag–Pol fusion protein DNA
vaccines, were determined by the unpaired Student’s t test
using JMP software (SAS Institute Inc., Cary, NC). Mixed
model analysis of variance (Winer, 1971) was used to
compare mean values of the rVV titers between control mice
and those immunized with the hGagp17p24–Polp51 and
hGag–polDFsDPr vaccines after challenge with vAbT141,
vAbT204, or vSC8.Acknowledgments
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